LABP
NASDAQLandos Biopharma Inc.
Landos Biopharma Inc. (LABP) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for LABP in the last 30 days. The most recent was published May 5, 2026.
News · 26 weeks10%
2026-05-032026-10-25
Mix090d
No activity.
Latest news
25 items- PRNImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBDNew data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn's disease A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn's disease patients I&I oral therapeutic
- PRNImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with u
- SECSEC Form 15-12G filed by Landos Biopharma Inc.15-12G - Landos Biopharma, Inc. (0001785345) (Filer)
- INSIDERSEC Form 4 filed by Callori Fred4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- INSIDERSEC Form 4 filed by Mayleben Timothy M4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- INSIDERSEC Form 4 filed by Girao Tiago4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- INSIDERSEC Form 4 filed by Batycky Alka4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- INSIDERSEC Form 4 filed by Garabedian Christopher Nishan4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- INSIDERSEC Form 4 filed by Adsett Roger4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- INSIDERSEC Form 4 filed by Cataldi Fabio4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- INSIDERSEC Form 4 filed by Oakes Gregory4 - Landos Biopharma, Inc. (0001785345) (Issuer)
- SECSEC Form RW filed by Landos Biopharma Inc.RW - Landos Biopharma, Inc. (0001785345) (Filer)
- SECSEC Form S-8 POS filed by Landos Biopharma Inc.S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
- SECSEC Form S-8 POS filed by Landos Biopharma Inc.S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
- SECSEC Form S-8 POS filed by Landos Biopharma Inc.S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
- SECSEC Form S-8 POS filed by Landos Biopharma Inc.S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)
- PRAbbVie Completes Acquisition of Landos Biopharma- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ:LABP). With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation,
- SECSEC Form 25-NSE filed by Landos Biopharma Inc.25-NSE - Landos Biopharma, Inc. (0001785345) (Subject)
- SECSEC Form 8-K filed by Landos Biopharma Inc.8-K - Landos Biopharma, Inc. (0001785345) (Filer)
- SECSEC Form 10-Q filed by Landos Biopharma Inc.10-Q - Landos Biopharma, Inc. (0001785345) (Filer)
- NEWSEx-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookFriday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92 billion. Sales were up 1.6% on an operational basis. “First quarter results were well ahead of our expectations, driven by excellent performance from our ex-Humira growth platform,” said Robert Michael, president and chief operating officer. The immunology portfolio generated $5.37 billion in sales, down 3.9% on a reported basis or 3.1% on an operational basis, due to Humira biosimilar competition. Humira revenues were $2.27 billion (down 35.9%), Skyrizi sales reached $2.01 billion
- SECSEC Form DEFM14A filed by Landos Biopharma Inc.DEFM14A - Landos Biopharma, Inc. (0001785345) (Filer)
- PRStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieMILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right
- SECSEC Form 10-K/A filed by Landos Biopharma Inc. (Amendment)10-K/A - Landos Biopharma, Inc. (0001785345) (Filer)
- SECSEC Form PREM14A filed by Landos Biopharma Inc.PREM14A - Landos Biopharma, Inc. (0001785345) (Filer)
LABP FAQ
8 questionsWhat does Landos Biopharma Inc. do?
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral...What is the latest news on LABP?
Quantisnow has not tracked any new filings, ratings or press releases for LABP in the last 30 days. The most recent wire item was published on May 5, 2026.Where does LABP stock trade?
Landos Biopharma Inc. (LABP) is listed on NASDAQ.What sector and industry is LABP in?
Landos Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Landos Biopharma Inc. go public?
Landos Biopharma Inc. (LABP) completed its IPO in 2021.What are analysts saying about LABP?
Landos Biopharma Inc. has had 7 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $140.00 price target on 2022-04-12.What companies are similar to LABP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LABP side-by-side with any of them on Quantisnow.How can I track LABP on Quantisnow?
Quantisnow aggregates Landos Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LABP to receive live email and push alerts on every new disclosure.